Cargando…

Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory

Detalles Bibliográficos
Autores principales:	Bhatt, Ankeet S., Dimond, Matthew, Fiuzat, Mona, Vaduganathan, Muthiah, Vardeny, Orly, Divanji, Punag, Komtebedde, Jan, Lefkowitz, Martin P., Nkulikiyinka, Richard, Petersson, Magnus, Roessig, Lothar, Schaber, Daniel, O’Connor, Christopher M., Solomon, Scott D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901495/ https://www.ncbi.nlm.nih.gov/pubmed/36754534 http://dx.doi.org/10.1016/j.jchf.2022.11.024

Ejemplares similares

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
por: Leiva, Orly, et al.
Publicado: (2020)

Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19
por: Abraham, William T., et al.
Publicado: (2020)

Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19
por: Abraham, William T., et al.
Publicado: (2020)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
por: Fiuzat, Mona, et al.
Publicado: (2022)

Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America
por: Bhatt, Ankeet S., et al.
Publicado: (2022)

The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2013)

Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches
por: Stienen, Susan, et al.
Publicado: (2020)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients?
por: Bhatt, Ankeet S., et al.
Publicado: (2020)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Update on Atrial Shunt Therapy for Treatment of Heart Failure
por: Litwin, Sheldon E., et al.
Publicado: (2022)

Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction
por: Ostrominski, John W., et al.
Publicado: (2022)

Vaccines, Antibodies and Donors: Varying Attitudes and Policies Surrounding COVID-19 and Heart Transplantation
por: DEFILIPPIS, ERSILIA M., et al.
Publicado: (2022)

The Intersection of Type 2 Myocardial Infarction and Heart Failure
por: McCarthy, Cian P., et al.
Publicado: (2021)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction
por: Harrington, Josephine, et al.
Publicado: (2023)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
por: Butt, Jawad H., et al.
Publicado: (2022)

Influenza vaccination: a ‘shot’ at INVESTing in cardiovascular health
por: Bhatt, Ankeet S, et al.
Publicado: (2021)

Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial
por: Jhund, Pardeep S., et al.
Publicado: (2023)

Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic
por: HALL, MICHAEL E., et al.
Publicado: (2020)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure
por: Frydas, Athanasios, et al.
Publicado: (2020)

Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure
por: Watanabe-Fujinuma, Emi, et al.
Publicado: (2020)

Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes
por: Desai, Rishi J., et al.
Publicado: (2020)

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
por: Pieske, Burkert, et al.
Publicado: (2017)

Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure: A Nationwide Readmissions Database Study
por: Arora, Sameer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j6qgfm39t4i40n24vsmhc6pnu8